Transcipt of the Company''s Earning call held on November 20, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro reported H1 FY26 revenue from operations of Rs. 34.41 crore, up 16.14% year-on-year, with EBITDA of Rs. 14.35 crore (up 17.36%) and PAT of Rs. 9.95 crore (up 17.20%), giving margins of 39% and 27% respectively. Export revenues grew 24% YoY led by stabilization in key markets, while the US subsidiary Axiodent posted ~47% growth despite tariff headwinds, managed via pricing realignment. Management highlighted new growth levers including 3D printers/scanners and digital dentistry, the newly commercialized disinfectant range, the Oradox oral care consumer brand, and biomaterials. Management guided for H2 FY26 revenue growth to cross 20% and a 3-year target of surpassing Rs. 100 crore in revenue, with bottom-line expected to grow faster than top-line given no major fresh capex planned.
Positive near-term outlook: management has guided for 20%+ H2 growth, margin protection, and a clear multi-year revenue scaling target, supported by new product verticals and export recovery. Stock may react favourably to the visible growth roadmap, though US tariff exposure remains a watchpoint.